TY - JOUR
T1 - Staphylococcal superantigens cause lethal pulmonary disease in rabbits
AU - Strandberg, Kristi L.
AU - Rotschafer, Jessica H.
AU - Vetter, Sara M.
AU - Buonpane, Rebecca A.
AU - Kranz, David M.
AU - Schlievert, Patrick M.
N1 - Financial support: US Public Health Service (research grants AI057153, AI074283, and AI064611) from the National Institute of Allergy and Infectious Diseases. P.M.S. and D.M.K. acknowledge membership in and support from the Region V “Great Lakes” Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium.
PY - 2010/12/1
Y1 - 2010/12/1
N2 - Background. The Centers for Disease Control and Prevention (CDC) and others reported that methicillin-resistant S. aureus (MRSA) are significant causes of serious human infections, including pulmonary illnesses. We investigated the role played by superantigens in lung-associated lethal illness in rabbits. Methods. A rabbit model was established to investigate the potential role played by superantigens, staphylococcal enterotoxin B (SEB), staphylococcal enterotoxin C (SEC), and toxic shock syndrome toxin-1 (TSST-1). Rabbits received intrabronchial community-associated (CA) MRSA strains USA200 (TSST-1 +), MW2 (SEC+), c99-529 (SEB+), or purified superantigens. Some rabbits were preimmunized against superantigens or treated with soluble high-affinity T cell receptors (Vβ-TCR) to neutralize SEB and then challenged intrabronchially with CA-MRSA or superantigens. Results. Rabbits challenged with CA-MRSA or superantigens developed fatal, pulmonary illnesses. Animals preimmunized against purified superantigens, or treated passively with Vβ-TCRs and then challenged with CA-MRSA or superantigens, survived. Lung histological analysis indicated that nonimmune animals developed lesions consistent with necrotizing pneumonia after challenge with CA-MRSA or purified superantigens. Superantigenimmune animals or animals treated with soluble Vβ-TCRs did not develop pulmonary lesions. Conclusions. Superantigens contribute to lethal pulmonary illnesses due to CA-MRSA; preexisting immunity to superantigens prevents lethality. Administration of high-affinity Vβ-TCR with specificity for SEB to nonimmune animals protects from lethal pulmonary illness resulting from SEB+ CA-MRSA and SEB.
AB - Background. The Centers for Disease Control and Prevention (CDC) and others reported that methicillin-resistant S. aureus (MRSA) are significant causes of serious human infections, including pulmonary illnesses. We investigated the role played by superantigens in lung-associated lethal illness in rabbits. Methods. A rabbit model was established to investigate the potential role played by superantigens, staphylococcal enterotoxin B (SEB), staphylococcal enterotoxin C (SEC), and toxic shock syndrome toxin-1 (TSST-1). Rabbits received intrabronchial community-associated (CA) MRSA strains USA200 (TSST-1 +), MW2 (SEC+), c99-529 (SEB+), or purified superantigens. Some rabbits were preimmunized against superantigens or treated with soluble high-affinity T cell receptors (Vβ-TCR) to neutralize SEB and then challenged intrabronchially with CA-MRSA or superantigens. Results. Rabbits challenged with CA-MRSA or superantigens developed fatal, pulmonary illnesses. Animals preimmunized against purified superantigens, or treated passively with Vβ-TCRs and then challenged with CA-MRSA or superantigens, survived. Lung histological analysis indicated that nonimmune animals developed lesions consistent with necrotizing pneumonia after challenge with CA-MRSA or purified superantigens. Superantigenimmune animals or animals treated with soluble Vβ-TCRs did not develop pulmonary lesions. Conclusions. Superantigens contribute to lethal pulmonary illnesses due to CA-MRSA; preexisting immunity to superantigens prevents lethality. Administration of high-affinity Vβ-TCR with specificity for SEB to nonimmune animals protects from lethal pulmonary illness resulting from SEB+ CA-MRSA and SEB.
UR - https://www.scopus.com/pages/publications/78649558101
UR - https://www.scopus.com/pages/publications/78649558101#tab=citedBy
U2 - 10.1086/657156
DO - 10.1086/657156
M3 - Article
C2 - 20979456
AN - SCOPUS:78649558101
SN - 0022-1899
VL - 202
SP - 1690
EP - 1697
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 11
ER -